The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Open accessAbstract
Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology. These effects are typically downstream consequences of suppression of cellular signalling pathways important in the regulation and maintenance of the microvasculature. Downregulation of these pathways in normal organs can lead to vascular disturbances and even regression of blood vessels, which could be intensified by concurrent pathological conditions. These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · cited 1×
“…www.bjcancer.com Published online 22 May 2007 & 2007 Cancer Research UK Keywords: angiogenesis inhibitors; VEGF signalling; capillaries Proliferation of new blood vessels is necessary for tumours to grow and contributes to the spread of blood-borne metastases (Folkman, 1971).”
BackgroundJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H.-P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,313
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Self-citationVEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Self-citationInai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Self-citationVEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 699
Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., Hainsworth, J. D., Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S., & Hurwitz, H. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20301 · Cited by 537
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
Schrijvers, B. F., Flyvbjerg, A., & De Vriese, A. S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00621.x · Cited by 504
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Role of VEGF-A in Vascularization of Pancreatic Islets
Lammert, E., Gu, G., McLaughlin, M., Brown, D., Brekken, R., Murtaugh, L. C., Gerber, H.-P., Ferrara, N., & Melton, D. A. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00378-6 · Cited by 384
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Baffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
Socinski, M. A., Novello, S., Brahmer, J. R., Rosell, R., Sanchez, J. M., Belani, C. P., Govindan, R., Atkins, J. N., Gillenwater, H. H., Pallares, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9303 · Cited by 323
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
Zachary, I. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1375 · Cited by 301
Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation
DeLeve, L. D., Wang, X., Hu, L., McCuskey, M. K., & McCuskey, R. S. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00017.2004 · Cited by 296
Managing Patients Treated with Bevacizumab Combination Therapy
Gordon, M. S., & Cunningham, D. (2005) · Oncology · doi:10.1159/000088481 · Cited by 283
Morabito, A., De Maio, E., Di Maio, M., Normanno, N., & Perrone, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-753 · Cited by 274
Horowitz, J. R., Rivard, A., van der Zee, R., Hariawala, M., Sheriff, D. D., Esakof, D. D., Chaudhry, G. M., Symes, J. F., & Isner, J. M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2793 · Cited by 266
Hurwitz, H., & Saini, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.001 · Cited by 179
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 170
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Tam, B. Y. Y., Wei, K., Rudge, J. S., Hoffman, J., Holash, J., Park, S.-K., Yuan, J., Hefner, C., Chartier, C., Lee, J.-S., et al. (2006) · Nature Medicine · doi:10.1038/nm1428 · Cited by 163
Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules
Baffert, F., Le, T., Thurston, G., & McDonald, D. M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00542.2005 · Cited by 157
Self-citationAllen, J. A., Adlakha, A., & Bergethon, P. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1475 · Cited by 145
Baffert, F., Thurston, G., Rochon-Duck, M., Le, T., Brekken, R. A., & McDonald, D. M. (2004) · Circulation Research · doi:10.1161/01.res.0000125295.43813.1f · Cited by 137
Self-citationThe Role of Vascular Endothelial Growth Factor in Wound Healing
Bates, D. O., & Jones, R. O. P. (2003) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734603256626 · Cited by 122
VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease
Lambrechts, D., & Carmeliet, P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.04.005 · Cited by 114
Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006
Govindarajan, R., Adusumilli, J., Baxter, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.4608 · Cited by 106
Socinski, M. A., Novello, S., Sanchez, J. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7001 · Cited by 101
Skillings, J. R., Johnson, D. H., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Holmgren, E. B., Holden, S. N., Hurwitz, H. I., & Scappaticci, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3019 · Cited by 95
Hedrick, E. E., Kozloff, M. F., Hainsworth, J. D., Badarinath, S., Cohn, A. L., Flynn, P. J., Dong, W., Suzuki, S., Sugrue, M. M., & Grothey, A. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3536 · Cited by 89
Therapeutic options to target angiogenesis in human malignancies
Herbst, R. S. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.4.635 · Cited by 77
Giantonio, B. J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.003 · Cited by 43
Cited by
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Metadata
- Authors
- Kamba, T., & McDonald, D. M.
- Venue
- British Journal of Cancer
- Published
- 2007-05-22
- Volume
- 96
- Issue
- 12
- Pages
- 1788-1795
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2056802932
- Cited by
- 990
- References
- 43
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.